Vladonix

Vladonix is a natural peptide complex derived from the thymus glands of young calves (no older than 12 months). It belongs to the "Cytomax" class of organ-specific peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson. The active fraction consists of low-molecular-weight polypeptides with a molecular mass up to 10,000 Da, which are described as selectively targeting immune system cells.

The proposed mechanism centers on the thymus gland's role as the primary organ of T-lymphocyte maturation. As the thymus undergoes progressive involution with age, output of naive T-cells declines, contributing to immunosenescence. The peptide fractions in Vladonix are held to bind to thymocyte membrane receptors and act as epigenetic regulators, stimulating transcription of genes involved in T-cell differentiation and cytokine signaling.

More specifically, the peptides are reported to: • Activate maturation and differentiation of T-lymphocytes • Increase the absolute counts of CD3+ and CD4+ (helper) T-cells • Normalize the CD4+/CD8+ (helper-to-suppressor) ratio • Regulate the balance of T- and B-lymphocytes • Stimulate interleukin-2 (IL-2) and interferon excretion in lymphocytes • Coordinate immune system function with neuroendocrine signaling

The mechanistic framework is analogous to, and partly extrapolated from, the better-characterized injectable thymic preparation Thymalin (Timalin), a related bovine thymus polypeptide complex whose cellular actions on cyclic nucleotides and cytokine release have been described in Russian bioregulator literature.

The direct clinical evidence for Vladonix is limited to a single small study conducted at the Medical Center of the Saint Petersburg Institute of Bioregulation and Gerontology (November 2003 to February 2004). The study enrolled 42 patients (23 men, 19 women; ages 34-65) who had experienced either long-term low-dose ionizing radiation exposure (n=22) or radiation and chemotherapy for cancer (n=20). A control group of 34 patients received standard treatment only. Patients in the treatment arm received Vladonix orally at 1-3 capsules two to three times daily before meals for 15-20 days, adjusted according to the severity of immune suppression.

Immunological outcomes were assessed by peripheral blood analysis, including CD3+, CD4+, CD8+, and CD20+ lymphocyte counts, immunoglobulin levels (IgM, IgG, IgA), and the leukocyte migration inhibition test with concanavalin A. The study reported that 78% of treated patients showed normalization of previously disrupted immune parameters, with statistically significant increases (P less than 0.05) in CD3+ and CD4+ lymphocyte counts and normalization of the CD4+/CD8+ ratio. Among oncology patients, 100% of the Vladonix group completed their radiation or chemotherapy course, compared with 79% of controls. No adverse effects, complications, or drug dependence were reported.

Important limitations must be stated plainly: this study was small and open-label, conducted by the same institution that develops and promotes the product, and has not been published in a peer-reviewed indexed journal. Independent replication has not been reported.

Broader context is provided by Khavinson and Morozov (2003, PMID 14523363), who assessed geroprotective effects of the injectable thymic preparation Thymalin and the pineal preparation Epithalamin in 266 elderly persons over 6-8 years. That study found a 2.0-2.1-fold reduction in mortality in the Thymalin group alone, and a 4.1-fold reduction with annual combined treatment over 6 years, alongside reductions in respiratory infections and cardiovascular disease incidence. Thymalin is a different pharmaceutical preparation from Vladonix; bioequivalence between the injectable polypeptide complex and the oral supplement has not been demonstrated.

Typical dosage: 10 mg (daily for cycles).

The single clinical study of Vladonix used 1-3 capsules (each containing 10 mg active peptide complex) taken orally two to three times daily before meals, for 15-20 days, with the dose calibrated to the degree of immune impairment. This represents the highest-intensity protocol documented in the literature and was used in a supervised clinical setting in patients with measurable immunosuppression.

Product labeling for Vladonix as sold commercially specifies 1-2 capsules (10-20 mg total) taken one to two times daily, 30 minutes before meals, for a one-month course.

Community-derived and practitioner-reported protocols circulating in the bioregulator user community typically describe: • Intensive initial course: 2 capsules daily for 30 days (one 60-capsule pack) • Maintenance course: 2 capsules daily for 10 days, repeated every three months • Some practitioners recommend two to three courses per year for general immune maintenance

Khavinson's own broader anti-aging protocols recommend Vladonix as part of combination regimens taken for one to two months, twice yearly.

There is no FDA-approved indication or prescribing information for Vladonix. It is sold as a food supplement in most markets. Dosage information above is drawn from manufacturer documentation and the single industry-affiliated clinical study. This content is provided for educational and reference purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare provider before using Vladonix or any peptide bioregulator.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The combination strategies for Vladonix originate primarily from Khavinson's own clinical recommendations and from practitioner and community protocols. Independent controlled evidence for any of these combinations does not exist; they should be regarded as anecdotal or expert opinion level.

Khavinson's own first-tier recommended combination for general anti-aging includes Vladonix alongside Endoluten (pineal gland bioregulator, A-8), Cerluten (cerebral cortex), Ventfort (vascular wall), Sigumir (cartilage and bone), and Svetinorm (liver) — taken for one to two months twice yearly. The rationale is organ-system coverage across multiple age-related decline pathways.

For immune-specific recovery, practitioners commonly suggest: • Vladonix plus Crystagen (a synthetic dipeptide Cytogen targeting immune cells) — the rationale is complementary activity at both the organ (thymus) and cellular (lymphocyte) levels • Vladonix plus Endoluten (pineal) plus Ventfort (vascular) — sold as an "immune system bundle" by several distributors, with the reasoning that pineal regulation of circadian immune rhythms and vascular support to lymphoid tissue potentiates thymic restoration • Vladonix plus Epitalon (a synthetic tetrapeptide analog of Epithalamin) — used in longevity-oriented protocols, with Epitalon providing telomerase activation and Vladonix contributing immune normalization

All combination protocols described above are based on theoretical organ-system synergy and practitioner experience. None have been evaluated in controlled trials.

Vladonix is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Generally well-tolerated

The 42-patient Vladonix clinical study reported no adverse effects, complications, contraindications, or drug dependence in treated participants. This is a consistent finding across Khavinson's research portfolio, though the study's small size and industry affiliation limit the strength of this conclusion.

Manufacturer-listed contraindications include: • Known hypersensitivity or individual intolerance to any product component • Pregnancy (insufficient safety data) • Lactation (insufficient safety data) • Children under 12 years of age

General safety considerations relevant to bovine-derived thymus extracts as a class: • There is a theoretical risk of contamination with prion proteins associated with bovine spongiform encephalopathy (BSE, "mad cow disease"). No cases of disease transmission to humans from thymus extract supplements have been documented; however, regulatory agencies including the FDA have issued guidance on sourcing and certification requirements for bovine-derived products. • Because Vladonix exerts immune-stimulating effects, it should be avoided in patients who have received organ transplants or allografts, as immune activation may precipitate graft rejection. • Concurrent use with immunosuppressant medications (cyclosporine, azathioprine, corticosteroids, mycophenolate, and similar agents) presents a moderate interaction risk: Vladonix's immunostimulatory action could counteract intended immunosuppression, increasing the risk of rejection or autoimmune flare. • Patients with active autoimmune conditions should use caution and consult a specialist, as stimulation of T-cell activity could theoretically exacerbate disease activity, though this has not been specifically documented for Vladonix. • One case of severe anaphylactic reaction to the related preparation thymostimulin (a thymic extract) has been documented in the broader thymic peptide literature, indicating that allergic responses, while rare, are possible.

No long-term safety studies beyond the Khavinson geroprotective trials (which used the pharmaceutical-grade injectable Thymalin, not Vladonix specifically) are available in the published literature.